During the treatment follow-up, there were highly significant differences between the level of CA9 gene expression in complete response (CR) and non-response (NR) AML patients conferring to a mean rank of 7.7 CR and 15.3 NR (p-value=0.006) (Figure 4). The gene discussed is CA9; the disease is acute myeloid leukemia.